Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Dermatology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for dermatologists to cover the diagnosis, treatment, follow-up, and clinical management of various skin conditions. Earning your CME/CE credit has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.
Please visit answersincme.com/860/MED-ONC-03814-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Neil D. Gross, MD, FACS; Nikhil I. Khushalani, MD; and Emily S. Ruiz, MD, MPH. In this activity, leading skin cancer experts guide an interactive, multidisciplinary case-based discussion on optimizing (neo)adjuvant immunotherapy for high-risk, resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Apply the latest clinical trial data and guideline recommendations to treatment planning for patients with high-risk, resectable CSCC; Recognize when to incorporate systemic neoadjuvant and adjuvant immunotherapy in patients with CSCC based on clinical and pathological features; and Propose strategies to optimize care for patients with high-risk CSCC through the evidence-based use of neoadjuvant and adjuvant immunotherapy within multidisciplinary care plans.
Please visit answersincme.com/860/2026-MC-001884-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Marc Serota, MD; Kristin Sokol, MD, MS, MPH; and Michelle Tarbox, MD. In this activity, experts in chronic spontaneous urticaria (CSU) discuss strategies to reduce diagnostic delays and how to personalize care beyond antihistamines. Upon completion of this activity, participants should be better able to: Recognize the impact of delayed diagnosis on disease control in patients with CSU; Review key inflammatory pathways—including type 2 inflammation—in CSU pathogenesis and how targeted therapies modulate them; Assess the latest clinical data for targeted therapies for the treatment of CSU; and Apply evidence-based strategies to personalize the management of antihistamine-refractory CSU.
Please visit answersincme.com/REE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Adam Friedman, MD. In this activity, an expert in the management of chronic spontaneous urticaria (CSU) discusses how targeted therapies fit within evolving treatment algorithms and how to integrate them appropriately into clinical practice for improved patient outcomes. Upon completion of this activity, participants should be better able to: Evaluate the rationale for targeted therapies in patients with CSU; Outline the different pathogenic mechanisms in CSU, with a focus on their relationship to type 2 inflammation, and the clinical implications of these different pathways; and Design treatment plans that optimize the use of targeted therapies in CSU, based on the latest evidence and expert insights.
Please visit answersincme.com/UZA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne Lynn S. Chang, MD and Zeynep Eroglu, MD. In this activity, experts in nonmelanoma skin cancer discuss clinical advances for the use of immunotherapy for the management of basal cell carcinoma (BCC). Upon completion of this activity, participants should be better able to: Evaluate current guideline-based recommendations for the use of immunotherapy in the management of basal cell carcinoma (BCC) across various stages of disease; Apply evidence-driven criteria to identify patients with BCC who may be appropriate candidates for immunotherapeutic intervention; and Determine real-world clinical approaches to optimize the benefit-risk profiles of immunotherapy in the management of BC.
Please visit answersincme.com/860/2026-MC-001755-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Linda Stein Gold, MD and Stephan Weidinger, MD, PhD. In this activity, experts in dermatology discuss the rationale and emerging clinical data supporting the use of OX40/OX40L inhibitors for the treatment of moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting the OX40/OX40L pathway to achieve durable response in the treatment of moderate to severe atopic dermatitis (AD); Review the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD management, including quality of life (QoL) impact; and Integrate QoL assessments into shared decision-making with patients who have moderate to severe AD.
Please visit answersincme.com/860/IME-020568-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jeffrey M. Cohen, MD, MPH; Kristine Kucera, PA-C, MPAS, DHSc; and Lauren E. Miller, MPAS, PA-C. In this activity, experts in dermatology discuss the evolving role of next-generation TYK2 inhibitors in the treatment of patients with moderate to severe psoriasis. Upon completion of this activity, participants should be better able to: Explain the clinical rationale for TYK2 inhibitors in the management of patients with moderate to severe psoriasis; Differentiate the mechanism of action of TYK2 inhibition from other oral treatment options used for patients with moderate to severe psoriasis; and Apply available clinical evidence to identify patients with moderate to severe plaque psoriasis who may be appropriate candidates for TYK2 inhibitor therapy within current treatment paradigms. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/MRQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alexandra K. Golant, MD; Peter Lio, MD, FAAD; and Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP. In this activity, experts in dermatology discuss the OX40L pathway and its potential role in the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting the OX40/OX40 ligand (OX40L) pathway in the treatment of moderate-to-severe atopic dermatitis (AD); Assess the evidence on efficacy outcomes and safety profiles of the emerging OX40/OX40L inhibitors in AD, including quality of life (QoL) impact; Integrate QoL assessments into shared decision-making with patients who have moderate or severe AD; and Outline strategies for enhancing the multidisciplinary management of moderate-to-severe AD.
Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis and care planning; Describe current and emerging treatment options for patients with AdvSM; and Evaluate patient- and disease-related strategies that inform treatment selection in AdvSM.
Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients’ quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM.
Please visit answersincme.com/860/IME-018263-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by April W. Armstrong, MD, MPH and Lawrence J. Green, MD. In this activity, experts in psoriasis review the latest evidence on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the treatment of patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and their relevance to clinical practice; and Review clinical trial data on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis.
Please visit answersincme.com/860/160204316-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tina Bhutani, MD, MAS, FAAD; and Robin K. Dore, MD. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.
Please visit answersincme.com/NEH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in rheumatology discusses strategies for the use of biologics, including IL-17 inhibitors, in the management of patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA). Upon completion of this activity, participants should be better able to: Recognize the rationale for IL-17 inhibition in the treatment of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA); Select appropriate biologic therapies for PsA and axSpA using current guidelines and patient-specific factors; and Outline patient-centered strategies for optimizing the management of PsA and axSpA.
Please visit answersincme.com/RTS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, a pediatrician and a pediatric dermatologist discuss strategies for optimizing biologic treatment for moderate to severe atopic dermatitis (AD). Upon completion of this activity, participants should be better able to: Recognize when treatment escalation to systemic therapy is warranted in pediatric patients with atopic dermatitis (AD); Select the optimal biologic for a given pediatric patient with moderate to severe AD; and Outline strategies to optimize biologic treatment in pediatric patients with moderate to severe AD. This activity is intended for US healthcare professionals only.
Please visit answersincme.com/860/99534447-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in dermatology and rheumatology discuss the use of TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA. Upon completion of this activity, participants should be better able to: Discuss the rationale for using novel TYK2 inhibitors in the treatment of patients with psoriatic disease, including PsA; Review the latest evidence on the use of novel TYK2 inhibitors in patients with psoriatic disease, including PsA; and Outline multidisciplinary strategies for the optimal integration of novel TYK2 inhibitors into treatment plans for patients with psoriatic disease, including PsA.
Please visit answersincme.com/860/99505211-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in psoriasis discuss real‑world strategies for using oral small molecules in moderate to severe disease. Upon completion of this activity, participants should be better able to: Identify patients with moderate to severe plaque psoriasis who would benefit from oral small molecule therapy; Differentiate the targets/mechanisms of action of available oral small molecule therapy for moderate to severe plaque psoriasis; and Integrate strategies to individualize oral small molecule therapy for moderate to severe plaque psoriasis, while balancing safety, considering regional barriers.
Please visit answersincme.com/GVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of melanoma discusses the clinical evidence for guideline-preferred first-line treatment options and factors informing treatment in metastatic or unresectable disease. Upon completion of this activity, participants should be better able to: Summarize efficacy and safety evidence on the guideline-preferred first-line therapies for metastatic or unresectable melanoma; and Review factors informing treatment selection among the guideline-preferred first-line therapies for patients with metastatic or unresectable melanoma.
Please visit answersincme.com/860/100752367-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the management of psoriatic disease discuss challenges in treatment, emerging TYK2 inhibitor therapies, and evidence-based strategies to optimize patient care. Upon completion of this activity, participants should be better able to: Recognize how nurse practitioners and physician associates can help address barriers to care and enhance outcomes for patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and explain the relevance of these distinctions in clinical outcomes; Evaluate the impact of emerging data on TYK2 inhibitors in shaping therapeutic strategies for psoriatic disease; and Apply strategies for aligning TYK2 inhibitor therapy with patient needs and multidisciplinary care plans.
Please visit answersincme.com/CAY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in melanoma discusses how to optimize the use of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable high-risk melanoma. Upon completion of this activity, participants should be better able to: Recognize recurrence patterns in patients with resected high-risk melanoma and the importance of timely referral to improve recurrence-free survival; Evaluate the risk-benefit profiles of neoadjuvant, adjuvant, or perioperative immunotherapy in patients with resectable stage IIB/C and stage III/IV melanoma; and Outline strategies to individualize the selection of neoadjuvant, adjuvant, or perioperative immunotherapy approaches for patients with resectable stage IIB/C and stage III/IV melanoma.
Please visit answersincme.com/860/99505211-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in psoriasis discuss real‑world strategies for using oral small molecules in moderate to severe disease. Upon completion of this activity, participants should be better able to: Identify patients with moderate to severe plaque psoriasis who would benefit from oral small molecule therapy; Differentiate the targets/mechanisms of action of available oral small molecule therapy for moderate to severe plaque psoriasis; and Integrate strategies to individualize oral small molecule therapy for moderate to severe plaque psoriasis, while balancing safety, considering regional barriers.
Please visit answersincme.com/860/TSG to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses evidence-based insights that inform the practical integration of adjuvant immunotherapy regimens into cutaneous squamous cell carcinoma (CSCC) care, based on available clinical data. Upon completion of this activity, participants should be better able to: Review the rationale for immunotherapy in the adjuvant treatment of patients with high-risk resected cutaneous squamous cell carcinoma (CSCC); Summarize the latest clinical trial data evaluating adjuvant immunotherapy in high-risk CSCC; and Outline evidence-based, multidisciplinary strategies to optimize the care of patients with high-risk CSCC in the adjuvant setting.
